ArticleFrontiers in immunology2022
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Methyl Caffeate Binds to IQGAP1 and Inhibits the Senescence-Associated Secretory Phenotype in Senescent Cells.International journal of molecular sciences · 2026Article
- Overcoming multidrug resistance Acinetobacter baumanii via downregulated virulence factor genes by green fabricated silver Nanoparticles mediated Piper nigrum.Scientific reports · 2026Article
- Capsular polysaccharides of Acinetobacter baumannii modulate antimicrobial resistance and innate immune response.Scientific reports · 2026Article
- Outer membrane vesicles of carbapenem-resistantMicrobiology spectrum · 2026Article
- In vitro interaction between Acinetobacter baumannii and human peripheral blood mononuclear cells.Archives of microbiology · 2026Article
- Inside Enemy Lines: Adhesion, Invasion, and Intracellular Persistence ofPathogens (Basel, Switzerland) · 2026Review
- UVB Upregulates Inflammatory Cytokines in Rosacea Cell Model by Promoting the Expression of TRPVs and TLR2.ImmunoTargets and therapy · 2026Article
- Identification of natural TLR4 modulators through network pharmacology and molecular modeling in SARS-CoV-2Frontiers in chemistry · 2026Article
- Metabolic Signatures of Acinetobacter baumannii and Klebsiella pneumoniae Infections in Acute-on-chronic Liver Failure.Cellular and molecular gastroenterology and hepatology · 2026Article
- NF-κB driven inflammation mediates loss of upper airway epithelial tolerance tobioRxiv : the preprint server for biology · 2025Article
- Enhancing Antimicrobial Susceptibility Testing for Acinetobacter baumannii Using Physiologically Relevant Culture Media and Biofilm Formation Assays.Current protocols · 2025Article
- IQGAP1 participates in bone marrow-derived macrophage recruitment and involves in liver inflammation/fibrosis.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Role of toll-like receptors in pulmonary immunity: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- The updated evidence of pirfenidone treated silicosis based on network pharmacology, molecular docking and experimental validation.Frontiers in medicine · 2025Article
- Experimental evolution under different nutritional conditions changes the genomic architecture and virulence of Acinetobacter baumannii.Communications biology · 2024Article
- Survival and virulence of Acinetobacter baumannii in microbial mixtures.BMC microbiology · 2024Article
- Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.Science China. Life sciences · 2024Article
- Pan-Genome Plasticity and Virulence Factors: A Natural Treasure Trove forAntibiotics (Basel, Switzerland) · 2024Review
- Outer Membrane Vesicles fromVaccines · 2023Review
- Virulence Factors and Pathogenicity Mechanisms ofAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary epithelial barrier dysfunction is a critical pathophysiological process in pneumonia and associated invasive infections, such as those caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.